Veracyte, Inc. (VCYT)
Market Cap | 3.04B |
Revenue (ttm) | 425.33M |
Net Income (ttm) | -9.27M |
Shares Out | 77.50M |
EPS (ttm) | -0.12 |
PE Ratio | n/a |
Forward PE | 43.09 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 631,375 |
Open | 39.16 |
Previous Close | 39.15 |
Day's Range | 38.61 - 39.80 |
52-Week Range | 18.61 - 41.43 |
Beta | 1.67 |
Analysts | Strong Buy |
Price Target | 40.00 (+2.04%) |
Earnings Date | Nov 6, 2024 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy... [Read more]
Financial Performance
In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price forecast is $40.0, which is an increase of 2.04% from the latest price.
News
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Veracyte Announces Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing bu...
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthc...
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 ...
New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate C...
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte appoints Brent Shafer and Tom Miller, Ph.D., to its board of directors.
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate ...
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte is Named a Greater Bay Area Top Workplace by the San Francisco Chronicle.
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer...
Veracyte Announces Second Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. “Our exceptional second quarter results are a ...
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, ...
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors.
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.
Veracyte Announces First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by robu...
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients.
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, M...
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance.
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024.
Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. “We closed 2023 with another...
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will pres...
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market o...
Veracyte Completes Acquisition of C2i Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes Acquisition of C2i Genomics.